INCHEON, Korea, November 11, 2025--(BUSINESS WIRE)--Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of ...
INCHEON, Korea, March 15, 2026--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a ...
Kan Hyeong-woo is a staff reporter at The Korea Herald, South Korea’s leading English-language daily. Based in Seoul, he covers technology, business and industry, with reporting spanning the gaming, ...
Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO. Byooviz is indicated for the treatment of ...
Samsung Bioepis Holdings said on the 11th that it established a subsidiary, EPIS NexLab, to pursue new future growth in bio. EPIS NexLab plans to push ahead with developing a bio-technology platform ...
About Samsung Epis Holdings Co., Ltd. As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value ...
Samsung Epis Holdings Co., Ltd. announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexLab will ...
Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. This press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results